Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1

H Maruta1

  • 1NF/TSC Cure Org., Melbourne, Australia.

Insights

Neurofibromatosis (NF) treatments targeting PAK1 show promise. Natural propolis extracts effectively suppress NF tumor growth with no side effects, offering a potential lifelong therapy for patients.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Neurofibromatosis (NF) comprises genetic disorders stemming from NF1 or NF2 gene dysfunction.
  • Both NF1 and NF2 gene dysfunctions lead to the abnormal activation of the oncogenic kinase PAK1, crucial for tumor growth.
  • Currently, no FDA-approved effective therapeutics exist for NF.

Purpose of the Study:

  • To introduce a series of anti-PAK1 agents as potential lifelong treatments for NF patients.
  • To evaluate the efficacy of synthetic and natural PAK1 inhibitors against NF tumors.

Main Methods:

  • Investigated the role of PAK1 in NF1 and NF2 tumor cell growth in vitro and in vivo.
  • Assessed the inhibitory effects of synthetic PAK1 blockers (FK228, PF3758309) and natural products (CAPE-based propolis extract 'Bio 30', ARC-based green propolis extract).

Main Results:

  • All tested PAK1 blockers, including natural products, suppressed NF tumor cell growth.
  • Propolis extracts (Bio 30 and GPE) are available and used for NF, TSC, and various PAK1-dependent cancers.
  • PAK1 is not essential for normal cell growth, suggesting propolis extracts have no side effects.

Conclusions:

  • Dysfunction of NF1 or NF2 genes converges on PAK1 activation, making it a therapeutic target for NF.
  • Natural propolis extracts demonstrate significant potential for the long-term management of NF and other PAK1-driven cancers.
  • The development of anti-PAK1 agents, particularly natural products, offers a promising therapeutic avenue for NF patients.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...